Suppr超能文献

成骨不全症中 FGFR3 突变的双重效应导致骨龄延迟。

Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.

机构信息

INSERM U781-Université Paris Descartes-Hôpital Necker-Enfants Malades, 75015 Paris, France.

出版信息

Bone. 2010 Nov;47(5):905-15. doi: 10.1016/j.bone.2010.07.020. Epub 2010 Jul 29.

Abstract

Achondroplasia (ACH), the most common form of human dwarfism is caused by a mutation in the Fibroblast Growth Factor Receptor 3 (FGFR3) gene, resulting in constitutive activation of the receptor. Typical radiological features include shortening of the tubular bones and macrocephaly, due to disruption of endochondral ossification. Consequently, FGFR3 has been described as a negative regulator of bone growth. Studying a large cohort of ACH patients, a delay in bone age was observed shortly after birth (for boys p=2.6×10(-9) and for girls p=1.2×10(-8)). This delay was no longer apparent during adolescence. In order to gain further insight into bone formation, bone development was studied in a murine model of chondrodysplasia (Fgfr3(Y367C/+)) from birth to 6weeks of age. Delayed bone age was also observed in Fgfr3(Y367C/+) mice at 1week of age followed by an accelerated secondary ossification center formation. A low level of chondrocyte proliferation was observed in the normal growth plate at birth, which increased with bone growth. In the pathological condition, a significantly high level of proliferative cells was present at birth, but exhibited a transient decrease only to rise again subsequently. Histological and in situ analyses suggested the altered endochondral ossification process may result from delayed chondrocyte differentiation, disruption of vascularization and osteoblast invasion of the femur. All these data provide evidence that FGFR3 regulates normal chondrocyte proliferation and differentiation during bone growth and suggest that constitutive activation of the receptor disrupts both processes. Therefore, the consequences of FGFR3 activation on the physiological process of bone development appear to be dependent on spatial and temporal occurrence. In conclusion, these observations support the notion that FGFR3 has a dual effect, as both a negative and a positive regulator of the endochondral ossification process during post-natal bone development.

摘要

软骨发育不全症(ACH)是最常见的人类侏儒症形式,由成纤维细胞生长因子受体 3(FGFR3)基因突变引起,导致受体的组成性激活。典型的放射学特征包括管状骨缩短和大头,这是由于软骨内骨化的破坏。因此,FGFR3 被描述为骨生长的负调节剂。通过研究大量 ACH 患者,发现出生后不久(男孩 p=2.6×10(-9),女孩 p=1.2×10(-8))就出现骨龄延迟。在青春期,这种延迟不再明显。为了进一步深入了解骨形成,研究了软骨发育不全症(Fgfr3(Y367C/+))的鼠模型中的骨发育,从出生到 6 周龄。在 1 周龄时,Fgfr3(Y367C/+) 小鼠也观察到骨龄延迟,随后加速了次级骨化中心的形成。在正常生长板中,出生时观察到软骨细胞增殖水平较低,随着骨生长而增加。在病理条件下,出生时存在大量增殖细胞,但仅短暂减少,随后再次增加。组织学和原位分析表明,改变的软骨内骨化过程可能是由于软骨细胞分化延迟、血管生成破坏以及成骨细胞侵入股骨。所有这些数据都表明,FGFR3 在骨生长过程中调节正常软骨细胞的增殖和分化,并表明受体的组成性激活会破坏这两个过程。因此,FGFR3 激活对骨发育生理过程的影响似乎取决于时空发生。总之,这些观察结果支持 FGFR3 具有双重作用的观点,即作为成纤维细胞生长因子受体 3(FGFR3)在出生后骨发育过程中既是软骨内骨化过程的负调节剂,也是正调节剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验